ME1100 (arbekacin inhalation solution)
Pulmonary infections caused by multidrug-resistant pathogens
Phase 3Active
Key Facts
Indication
Pulmonary infections caused by multidrug-resistant pathogens
Phase
Phase 3
Status
Active
Company
About Meiji Seika Pharma
Japanese pharmaceutical company developing innovative anti-infectives and oncology drugs through small molecule discovery platforms.
View full company profile